Praxis Precision Medicines, Inc. Common Stock
PRAXPraxis Precision Medicines, Inc. (PRAX) is a biotechnology company focused on developing targeted therapies for neuroscience and rare diseases. The company leverages precision medicine approaches to create treatments tailored to specific genetic and molecular profiles, aiming to improve outcomes for patients with neurological and neuropsychiatric conditions.
Company News
Praxis Precision Medicines (NASDAQ: PRAX) shares surged 7.15% on Tuesday following FDA acceptance of its New Drug Application for ulixacaltamide, a treatment for essential tremor, with an FDA decision target date of January 29, 2027. The company also reported positive Phase 3 trial results and significant seizure reduction data from its elsunerse...
Praxis Precision Medicines announced positive Phase 1/2 trial results for elsunersen (PRAX-222), an antisense oligonucleotide treatment for SCN2A developmental and epileptic encephalopathy. The drug demonstrated a 77% placebo-adjusted seizure reduction, with 71% of treated patients achieving >50% seizure reduction. All elsunersen-treated patients...
Cormorant Asset Management sold 50,000 shares of Praxis Precision Medicines (PRAX) in Q4 2025 for $9.31 million, but the position still increased by $227 million in value due to stock appreciation. PRAX remains Cormorant's largest holding at $280 million. The biotech stock has surged 700% over the past year and is advancing multiple late-stage th...
Deerfield Management Company increased its stake in Praxis Precision Medicines by 62,500 shares, bringing its total position to $266.25 million. PRAX stock has surged 685% over the past year, significantly outperforming the S&P 500. The biotech company recently submitted FDA applications for two drug candidates and has four leading programs that ...
Praxis Precision Medicines (PRAX) has surged 685% over the past year, attracting an $80.5 million investment from Driehaus Capital Management. The clinical-stage biotech company recently submitted two FDA applications for therapies targeting essential tremor and rare developmental epilepsies. With $926 million in cash and potential revenue exceed...
